We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lung perfusion assessed by SPECT/CT after a minimum of three months anticoagulation therapy in patients with SARS-CoV-2-associated acute pulmonary embolism: a retrospective observational study.
- Authors
Berghaus, Thomas M.; Bader, Stefanie; Faul, Christian; Haberl, Sabine; Schwarz, Florian; Liebich, Alessandro; Dierks, Alexander; Kircher, Malte; Lapa, Constantin; Pfob, Christian H.
- Abstract
<bold>Background: </bold>Anticoagulant treatment is recommended for at least three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related acute pulmonary embolism (PE), but the persistent pulmonary clot burden after that time is unknown.<bold>Methods: </bold>Lung perfusion was assessed by ventilation-perfusion (V/Q) SPECT/CT in 20 consecutive patients with SARS-CoV-2-associated acute PE after a minimum of three months anticoagulation therapy in a retrospective observational study.<bold>Results: </bold>Remaining perfusion defects after a median treatment period of six months were observed in only two patients. All patients (13 men, seven women, mean age 55.6 ± 14.5 years) were on non-vitamin K direct oral anticoagulants (DOACs). No recurrent venous thromboembolism or anticoagulant-related bleeding complications were observed. Among patients with partial clinical recovery, high-risk PE and persistent pulmonary infiltrates were significantly more frequent (p < 0.001, respectively).<bold>Interpretation: </bold>Temporary DOAC treatment seems to be safe and efficacious for resolving pulmonary clot burden in SARS-CoV-2-associated acute PE. Partial clinical recovery is more likely caused by prolonged SARS-CoV-2-related parenchymal lung damage rather than by persistent pulmonary perfusion defects.
- Publication
Respiratory Research, 2022, Vol 23, Issue 1, p1
- ISSN
1465-9921
- Publication type
Article
- DOI
10.1186/s12931-022-02188-2